Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | SHR-1316 + SHR1501 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SHR-1316 | SHR 1316|SHR1316|Adebrelimab|HTI 1088|HTI-1088|HTI1088 | Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 119 | SHR-1316 is a monoclonal antibody that targets PD-L1 (CD274), potentially resulting in antitumor activity (PMID: 33760397). | |
SHR1501 | SHR 1501|SHR-1501 | SHR1501 is a fusion protein comprised of IL-15 linked to the sushi domain of the IL-15 receptor alpha, which may activate an antitumor immune response, thereby leading to enhanced killing and reduced proliferation of tumor cells (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03995472 | Phase I | SHR-1316 + SHR1501 | A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors | Completed | AUS | 1 |